Breaks Categories: News

ThursdayOct 12, 2023 1:31 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) K5 ASRs and K1B Emergency Communications Systems Deployed for New and Existing Customers

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, announced two new sales for its K5 ASRs and an expansion sale from an existing user of its K1B line of emergency communication systems. The announcement reads, “Two Portland, Oregon, hotels each signed contracts for Knightscope ASRs to patrol their parking areas after the word-of-mouth-success of another Portland area hotel. Security in hospitality encompasses a hotel’s building and grounds as well as its guests, employees, visitors and day users. As recently outlined in Knightscope’s Blog, operators and administrators must follow an integrated approach…

Continue Reading

ThursdayOct 12, 2023 1:17 pm

NetworkNewsBreaks – Nate’s Food Co. (NHMD) Issues Shareholder Update

Nate’s Food Co. (OTC: NHMD), a dynamic food manufacturer and distributor, today announced that it has filed a Form 8-K with the Securities and Exchange Commission that provides details on the company’s corporate charter amendment that has been filed with the Colorado Secretary of State. According to the announcement, the charter amendment formalizes the company’s commitment not to engage in a reverse stock split of its common stock before Jan. 1, 2025, unless the company is uplisting to NASDAQ or the NYSE. To view the full press release, visit https://nnw.fm/mFQls About Nate’s Food Co. Nate’s is a dynamic food manufacturer…

Continue Reading

ThursdayOct 12, 2023 12:58 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted patents. According to the update, Canadian Patent #2,984,917, “ Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents, ” was granted on Sept. 26, 2023, and expires Dec. 1, 2036. The patent recognizes Lexaria’s innovations in delivering lipophilic (fat-based) active drugs and active molecules suspended in a water-based format. Lexaria’s DehydraTECH technology can be used in dry formats such as capsules and pills, as well as…

Continue Reading

ThursdayOct 12, 2023 12:01 pm

NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a definitive agreement for the issuance and sale shares of its common stock. Specifically, the agreement calls for the issue and sale of 2,424,243 shares of Class A common stock, or common stock equivalents, for $1.65 per share in a registered direct offering. The announcement also noted that a concurrent private placement calling for Longeveron to issue and sell unregistered Series A warrants to purchase up to 2,424,243 shares…

Continue Reading

ThursdayOct 12, 2023 11:30 am

NetworkNewsBreaks – Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) Announces Positive BFS for Crawford Project

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF) today released results from the bankable feasibility study (“BFS”) for its innovative and wholly owned Crawford Nickel Sulphide Project (“Crawford”). According to the announcement, the results confirm significantly improved economics from its preliminary economic analysis (“PEA”), with an after-tax NPV 8% of $2.5 billion and IRR of 17.1%. Ausenco Engineering Canada Inc. prepared the BFS in accordance with National Instrument 43-101 (“NI 43-101”). “This bankable feasibility study is a significant milestone for Crawford and a major step forward in demonstrating the value of our Timmins Nickel District and its potential to anchor a Zero…

Continue Reading

ThursdayOct 12, 2023 11:14 am

NetworkNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Reaches Agreement Regarding Reorganization of Three US Subsidiaries

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has announced a prepackaged reorganization of some of its subsidiaries. Those subsidiaries include RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals Inc. and RVL Pharmacy, LLC. According to the announcement, a change of control transaction agreement was reached with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”) and other key stakeholders. The transaction will be made through through prepackaged bankruptcy cases that have begun in the U.S. Bankruptcy Court…

Continue Reading

ThursdayOct 12, 2023 10:55 am

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), Satispay Collaboration Results in Quantum-Hybrid App that Optimizes Customer Rewards Initiatives

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, is working with Satispay, the leading Italian fintech unicorn revolutionizing mobile payments. The two companies have built a quantum-hybrid application designed to optimize customer rewards initiatives. According to the announcement, the quantum-optimized rewards application shows 50% improvement in customer rewards programs for the same amount of budget. The announcement noted that Satispay has plans to transition the quantum-hybrid application into production. Satispay is seeing increased adoption of its services in countries such as Italy and France as users look…

Continue Reading

WednesdayOct 11, 2023 1:50 pm

NetworkNewsBreaks – Untraceable’s Flagship Conference Showcases Ever-Rising Possibilities Unlocked by Blockchain Technologies

Untraceable’s flagship event, the Blockchain Futurist Conference, recently took the spotlight at the iconic Rebel Entertainment Complex and Cabana Pool Bar. As the largest Web3 gathering in Canadian history, this year’s conference brought together global thought leaders and industry luminaries to explore the rapidly evolving technological landscape, hidden opportunities and an increasing number of innovative applications. Thousands of attendees (including developers, visionaries, startup entrepreneurs, investors, financial institutions representatives, technology enthusiasts and nearly 200 speakers) joined the conference, a cornerstone of Canada Crypto Week. IBN’s CryptoCurrencyWire served as an official newswire and a key sponsor of the event, and Jonathan Keim,…

Continue Reading

WednesdayOct 11, 2023 1:44 pm

NetworkNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Appoints Intel Capital Cofounder to Board

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company's strategy and business development efforts. Miller’s impressive decades-long career includes strategic and responsible roles in both the technology and medical industries. After spending 13 years in the medical science space, he moved to high tech where, in addition to cofounding Intel Capital, he served as the company’s corporate vice president of…

Continue Reading

WednesdayOct 11, 2023 1:35 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including…

Continue Reading